Research programme: AAV based gene therapies- Affinia Therapeutics
Latest Information Update: 25 Oct 2024
At a glance
- Originator AFFINIA THERAPEUTICS
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiomyopathies; CNS disorders; Musculoskeletal disorders
Most Recent Events
- 22 Oct 2024 Pharmacodynamics data from a preclinical trial in CNS disorders released by Affinia Therapeutics
- 17 May 2024 Pharmacodynamics and adverse events data from preclinical studies in Amyotrophic lateral sclerosis and Cardiomyopathies released by Affinia Therapeutics
- 22 Apr 2024 Preclinical trials in Cardiomyopathies in USA (Parenteral) before April 2024